No approved hantavirus vaccine exists for general use in the United States or most Western countries as of mid-2026, driving the 94.5% market-implied probability against availability by year-end. Vaccine candidates remain in preclinical or early clinical stages, including mRNA platforms tested in animal models and DNA vaccines that have completed only Phase 1 or Phase 2 immunogenicity studies without advancing to large-scale efficacy trials. Standard regulatory pathways demand completed Phase 3 data demonstrating safety and protection against hantavirus pulmonary syndrome, followed by FDA or EMA review—timelines that exceed remaining months even under accelerated review. Recent structural biology advances and single-dose mRNA findings in hamsters offer promising leads but require years of further human testing. A breakthrough regulatory designation or emergency authorization could theoretically shift outcomes, though current pipelines show no such pathway.